Shares in research provider Horizon Discovery (HZD) rose 5 per cent after the group signed a licence and supply deal with Aim-traded Abcam (ABC). Under the new arrangement, Abcam will have access to over 1,800 cell-line models from Horizon's collection, which will aid the larger group to validate antibodies which it currently markets and sells to global research institutions.
IC TIP:
Buy
at
164p
Horizon will receive £660,000 across an initial three-year term, with another £1.3m across years four to six if Abcam extends the contract.
